Results 51 to 60 of about 2,118 (199)

Refractoriness to platelet transfusion after single-donor consecutive platelet transfusions and its relationship to platelet antibodies [PDF]

Journal of Korean Medical Science, 1988
In thirty patients with acute leukemia and severe aplastic anemia receiving random single donor platelet transfusions, the development of refractoriness by consecutive platelet transfusions with cytapheresis and its relationship to the appearance of anti-platelet antibodies were investigated.
M, Lee, B K, Kim, S, Park, C, Suh, M H, Park, M J, Cho   +5 more
openaire   +2 more sources

Semi‐mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and Azacitidine

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 448-459, March 2025.
Abstract Myelodysplastic syndromes (MDS) represent a group of bone marrow disorders involving cytopenias, hypercellular bone marrow, and dysplastic hematopoietic progenitors. MDS remains a challenge to treat due to the complex interplay between disease‐induced and treatment‐related cytopenias.
Neha Thakre, Corinna Maier, Jiuhong Zha, Benjamin Engelhardt, Johannes E. Wolff, Sven Mensing   +5 more
wiley   +1 more source

The international, prospective Glanzmann Thrombasthenia Registry: treatment and outcomes in surgical intervention

Haematologica, 2015
Standard treatment for Glanzmann thrombasthenia, a severe inherited bleeding disorder, is platelet transfusion. Recombinant factor VIIa is reported to be effective in Glanzmann thrombasthenia with platelet antibodies and/or refractoriness to platelet ...
Man-Chiu Poon, Roseline d’Oiron, Rainer B. Zotz, Niels Bindslev, Matteo Nicola Dario Di Minno, Giovanni Di Minno   +5 more
doaj   +1 more source

Nonthermal plasma approaches for combating implant‐associated infections: A compendious review

VIEW, EarlyView.
Implant‐associated infections pose serious clinical challenges. Non‐thermal plasma (NTP) modifications overcome this bottleneck in distinct ways relative to traditional sterilization methods. Gas‐phase plasmas generate highly energetic species, UV radiation and reactive oxygen/nitrogen species (RONS), which alter the implant surface properties.
A. M. Trimukhe, Satish Rojekar, Amol Gholap, K. Navaneetha Pandiyaraj, Mukesh Patekar, Claudia Riccardi, R. R. Deshmukh, Tomáš Kovářík, Kalim Deshmukh   +8 more
wiley   +1 more source

Myeloablative Busulfan, Fludarabine and Melphalan Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Childhood Myeloid Malignancy

Asia-Pacific Journal of Clinical Oncology, EarlyView.
We report our single‐center experience of transplant outcomes with a busulfan, fludarabine and melphalan‐based conditioning regimen for children < 18 years of age. The regimen was shown to be well tolerated and effective for heavily pretreated children with high‐risk myeloid malignancies prior to allogeneic hematopoietic stem cell transplant.
Mayank Dhamija, Fiona Kerr, Hazel Gough, Johnathan Soggee, Laurence C. Cheung, Rishi S. Kotecha, Shanti Ramachandran   +6 more
wiley   +1 more source

Application and analysis of compatible platelets matching via antigen avoidance

Zhongguo shuxue zazhi
[Objective] To investigate the application of antigen avoidance pattern for compatible platelets matching. [Methods] Samples from two patients with immune-mediated platelet transfusion refractoriness were screened for platelet antibodies using solid ...
WU Shaoyun, ZHENG Jianxun, JIANG Sujun, WU Shiquan   +3 more
doaj   +1 more source

Clinical and immunological effects of adding cyclophosphamide to pomalidomide–dexamethasone in relapsed‐refractory multiple myeloma: The randomized MUKseven trial

British Journal of Haematology, EarlyView.
Summary There is an ongoing need for accessible combination therapies for patients with relapsed‐refractory multiple myeloma (RRMM), alongside a growing interest in understanding their immunological effects, particularly on T‐cell populations. Myeloma UK (MUK) MUKseven (NCT02406222) was an academic, UK multicentre randomized controlled, open‐label ...
Andrew Hall, James Croft, Katrina Walker, Kevin Boyd, Sadie Roberts, Amy Holroyd, Mamta Garg, Elsa Ferris, Gordon Cook, William E. Pierceall, Anjan Thakurta, Anita Gandhi, Charlotte Pawlyn, Sarah R. Brown, Martin Kaiser   +14 more
wiley   +1 more source

Platelet Transfusion: And Update on Challenges and Outcomes

Journal of Blood Medicine, 2020
Pilar Solves Alcaina Blood Bank, Hematology Service, Hospital Universitari I Politècnic La Fe, Valencia, CIBERONC, Instituto Carlos III, Madrid, SpainCorrespondence: Pilar Solves AlcainaBlood Bank, Hematology Service, Hospital Universitari I Polit&
Solves Alcaina P
doaj  

Integrating novel therapeutic strategies in myeloproliferative neoplasms: Driving disease‐directed progress

British Journal of Haematology, EarlyView.
Summary Over the past decade, there has been a substantial increase in the diversity and number of therapeutic options for myeloproliferative neoplasms (MPNs). While many remain within the clinical trial arena, the clinician and patient community have seen more approvals reaching the clinic and a rethink on how best we should be approaching these ...
Trung Q. Ngo, Maria Georgiou, Donal P. McLornan, Claire N. Harrison   +3 more
wiley   +1 more source

Identification of platelet refractoriness in oncohematologic patients

Clinics, 2011
OBJECTIVES: To identify the occurrence and the causes of platelet refractoriness in oncohematologic patients. INTRODUCTION: Platelet refractoriness (unsatisfactory post-transfusion platelet increment) is a severe problem that impairs the treatment of ...
Aline Aparecida Ferreira, Roberto Zulli, Sheila Soares, Vagner de Castro, Helio Moraes-Souza   +4 more
doaj